This latter group of mutations are overrepresented, a result that is determined by the substantial prevalence of TRAF3 mutations in both MMCLs (one third of mutations) and MM tumors (>50% of mutations) [29, 30, 62]. This evidence concerns the gene TRAF3 and Miyoshi myopathy.